Abstract
The ability of the atypical antipsychotic drug candidate olanzapine to antagonize dopamine, serotonin, α-adrenergic and muscarinic receptors in vivo was assessed by various neurochemical measurements in rat brain. Olanzapine increased the concentrations of the dopamine metabolites DOPAC and HVA in striatum and nucleus accumbens. Olanzapine antagonized the pergolide-induced decrease of striatal DOPA concentrations in rats treated with gammabutyrolactone and NSD1015 and increased striatal 3-methoxytyramine concentrations in nomifensine-treated rats (but not after gammabutyrolactone administration), suggesting that olanzapine blocked terminal and somatodendritic autoreceptors on dopamine neurons. Inactivation of dopamine D1 and D2 receptors by EEDQ was antagonized by olanzapine. The ex vivo binding of the 5HT2 radioligand [3H]-ketanserin was inhibited by olanzapine treatment, as was quipazine-induced increases in MHPG-SO4, evidence suggesting that olanzapine antagonized 5HT2 receptors. At higher doses, olanzapine increased the concentration of the norepinephrine metabolite, MHPG-SO4, probably by blocking α1-adrenergic receptors. Olanzapine inhibited ex vivo binding of the muscarinic antagonist radioligand [3H]-pirenzepine and lowered concentrations of striatal, but not hippocampal, acetylcholine levels. The findings provide evidence that olanzapine antagonized dopamine, serotonin, α-adrenergic and muscarinic receptors in vivo, consistent with its high affinity for these receptor sites in vitro.
Similar content being viewed by others
References
Altar CA, Wasley AM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16: 517–525
Andersen PH, Nielsen EB, Gronvald FC, Braestrup C (1986) Some atypical neuroleptics inhibit [3H]SCH23390 binding in vivo. Eur J Pharmacol 120: 143–144
Beasley CM, Tollefson GD, Tran P, Satterlee W, Sanger T, Holman S and the olanzapine HGAD Study Group (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology 14: 111–123
Benvenga MJ, Leander JD (1995) Olanzapine increases rates of punished responding in pigeons. Psychopharmacology 119: 133–138
Bymaster FP, Heath I, Hendrix JC, Shannon HE (1993) Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267: 16–24
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87–96
Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607–1619
Cohen BM, Lipinski JF (1986) In vivo potencies of antipsychotic drugs in blocking alpha-1 noradrenergic and dopamine D2 receptors: implications for drug mechanism of action. Life Sci 39: 2571–2580
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483
Demarest KT, Moore KE (1980) Accumulation ofl-dopa in the median eminence: an index of tuberoinfundibular dopaminergic nerve activity. Endocrinology 106: 463–468
Fuller RW, Perry KW (1989) Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J Pharmacol Exp Ther 248: 50–56
Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Res Comm Chem Pathol Pharmacol 77: 87–93
Fuller RW, Snoddy HD, Perry KW (1978) Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart. Arch Int Pharmacodyn Ther 231: 30–41
Fuller RW, Clemens JA, Kornfeld ED, Snoddy HD, Smalstig EB, Bach NJ (1979) Effect of (8β)-8-[(methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sci 24: 375–382
Heal DJ, Czudek C, Buckett WR (1994) Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Prog Neuropsychopharmacol Biol Psychiatry 18: 803–821
Heal DJ, Frankland ATJ, Buckett WR (1990) A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology 29: 1141–1150
Hemrick-Luecke SK, Bymaster FP, Falcone JF, Moore NA, Tye NC, Fuller RW (1993) Effect of olanzapine on rat brain receptor binding, acetylcholine levels and monoamine turnover. Soc Neurosci Abstr 19: 383
Hemrick-Luecke SK, Snoddy HD, Fuller RW (1994) Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 55: 479–483
Marchi M, Raiteri M (1985) On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties. J Pharmacol Exp Ther 235: 230–233
Martin GE, Williams M, Haubrich DR (1982) A pharmacologic comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) andN-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists. J Pharmacol Exp Ther 223: 298–304
McGeer PL, Grewaal DS, McGeer EG (1974) Influence of noncholinergic drugs on rat striatal acetylcholine levels. Brain Res 80: 211–217
McKinney M, Miller JH, Aagaard PJ (1993) Pharmacological characterization of the rat hippocampal autoreceptor. J Pharmacol Exp Ther 264: 74–78
McMillen BA, Shore P (1978) Comparative effects of clozapine and α-adrenergic blocking drugs on regional noradrenaline metabolism in rat brain. Eur J Pharmacol 52: 225–230
Meek JL, Neff NH (1973) The rate of formation of 3-methoxy-4-hydroxyphenylethyleneglycol sulfate in brain as an estimate of the rate of formation of norepinephrine. J Pharmacol Exp Ther 184: 570–575
Meller E, Bohmaker K, Goldstein M, Friedhoff AJ (1985) Inactivation of D1 and D2 dopamine receptors byN-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. J Pharmacol Exp Ther 233: 656–662
Meltzer HY, Matsubara S, Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238–246
Miller RJ, Hiley CR (1974) Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248: 596–597
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262: 545–551
Moore NA, Calligaro DO, Wong DT, Bymaster FP, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2: 281–293
Moore NA, Rees G, Sanger G, Tye NC (1994) Effect of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5: 196–202
Nyberg S, Farde L, Halldin C (1996) A PET study of 5-HT2 and D2 receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology (in press)
Obermeyer BD, Nyhart EH, Mattiuz EL, Goodwin M, Barton RD, Breau AP, Gillespie TA, Binkley SN, Reubin A, Lemberger L (1993) The disposition of olanzapine in healthy volunteers. Pharmacologist 35: 176
Perry KW, Fuller RW (1991) Serotonergic drugs increase MHPG-SO4 in rat hypothalamus. Soc Neurosci Abstr 17: 1178
Przegalinski E, Kordecka-Magiera A, Mogilnicka E, Maj J (1981) Chronic treatment with some atypical antidepressants increases the brain level of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rats. Psychopharmacology 74: 187–190
Rasmussen K, Aghajanian GK (1988) Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5HT2 binding affinity. Neuropsychopharmacology 1: 101–107
Roth RH, Wolf ME, Deutch AY (1987) Neurochemistry of midbrain dopamine systems. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 81–94
Sacaan AI, Bymaster FP, Schoepp DD (1992) Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by dopamine. J Neurochem 59: 245–251
Saller CF, Salama AI (1986) 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds. Naunyn-Schmiedeberg's Arch Pharmacol 334: 125–132
Seeman P, Lee T, Chang-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717–718
Sethy VH, Van Woert MH (1973) Antimuscarinic drugs-effect on brain acetylcholine and tremors in rats. Biochem Pharmacol 22: 2685–2691
Sethy VH, Van Woert MH (1974) Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists. Res Comm Chem Pathol Pharmacol 8: 13–28
Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14: 92–104
Umezu K, Moore KE (1979) Effects of drugs on regional brain concentrations of dopamine and dihydroxyphenylacetic acid. J Pharmacol Exp Ther 208: 49–56
Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614
Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: similar biochemical and histochemical effects of γ-hydroxy-butyrate and acute lesions of the nigro-neostriatal pathway. J Pharmacol Exp Ther 186: 630–639
Westerink BHC (1985) Sequence and significance of dopamine metabolism in the rat brain. Neurochem Int 7: 221–227
Zetterstrom T, Sharp T, Ungerstedt U (1985) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 106: 27–37
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bymaster, F.P., Hemrick-Luecke, S.K., Perry, K.W. et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124, 87–94 (1996). https://doi.org/10.1007/BF02245608
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245608